From the secondary analysis, the considerably less conservative but clinically meaningful criterion of secure response (outlined being a 50% or more reduction in MADRS from baseline for 2 weeks) was used. With the patients who reached stable reaction, 25.eight% within the esketamine group and fifty seven.6% in the placebo group https://motheru000pfv9.blogchaat.com/profile